MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment

(2015) Yang Yang et al.   NEOPLASIA

RAS/RAF/MEK Inhibitors in Oncology

(2012) M. Broggini   CURRENT MEDICINAL CHEMISTRY

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer

(2011) Jean-Pierre Gillet et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Insulin receptor and cancer

(2011) A. Belfiore et al.   ENDOCRINE-RELATED CANCER

Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions

(2011) Jean-Pierre Gillet et al.   MOLECULAR PHARMACEUTICS

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Chemical phylogenetics of histone deacetylases

(2010) James E Bradner et al.   Nature Chemical Biology

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

(2010) Jieru Meng et al.   PLoS One

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

(2009) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

(2009) Annette S. Gillings et al.   FEBS Journal

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database

(2009) J. N. Orina et al.   MOLECULAR CANCER THERAPEUTICS

Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

(2008) V. R. Fantin et al.   CANCER RESEARCH

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

(2008) A. Newbold et al.   MOLECULAR CANCER THERAPEUTICS